Cumulative Clinical Trial Experience with Levofloxacin for Patients with Community-Acquired Pneumonia-Associated Pneumococcal Bacteremia
Abstract
Streptococcus pneumoniae has been isolated in up to two-thirds of all cases of community-acquired pneumonia (CAP), and pneumococcal bacteremia has been associated in 20%–25% of these cases. The recent literature has suggested that better outcomes are achieved with the use of combination therapy for the treatment of pneumococcal bacteremia. The present study analyzed the efficacy of levofloxacin monotherapy in the treatment of patients with a diagnosis of pneumococcal bacteremia who participated in clinical trials for the treatment of CAP. A total of 108 patients from 9 clinical trials were identified as having pneumococcal bacteremia, including 12 patients infected with penicillin- ormacrolide-resistant strains. Overall, 98 (90.7%) of 108 microbiologically evaluable patients had a successful clinical response, including 11 (91.7%) of 12 patients infected with a macrolide- or penicillin-resistant strain. The mortality rate in this population was <1%. The present study suggests that levofloxacin monotherapy can be an effective choice for the treatment of CAP-associated pneumococcal bacteremia.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.